News for Healthier Living

Rethinking Triple-Negative Breast Cancer Treatment Through EGFR Co-Targeting and Nanotechnology

Triple-negative breast cancer (TNBC) remains one of the most challenging forms of breast cancer to treat because it lacks the estrogen, progesterone and HER2 receptors that enable targeted treatment in other breast cancer subtypes. A review published in Genes & Diseases examines how targeting the epidermal growth factor receptor (EGFR) alongside other molecular targets, supported by nanocarrier-based delivery, could offer new possibilities for more precise TNBC treatment.

September 25, 2026


October 2 2026

October 1 2026

September 30 2026

September 29 2026

September 28 2026

September 27 2026

September 25 2026

September 24 2026

September 23 2026

September 22 2026

September 21 2026